NCT03897803

Brief Summary

The aim of our study was to assess the performance of compression-strain US elastography in patients with idiopathic inflammatory myopathies over time and to study these findings with clinical and functional parameters as well as biochemical and electromyographic tests.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 29, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 1, 2019

Completed
14 days until next milestone

Study Start

First participant enrolled

April 15, 2019

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

October 19, 2020

Status Verified

October 1, 2020

Enrollment Period

1.6 years

First QC Date

March 29, 2019

Last Update Submit

October 16, 2020

Conditions

Outcome Measures

Primary Outcomes (16)

  • Manual muscle testing

    Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)

    6 months

  • Serum creatine kinase (CK) levels

    CK measured in U/L using ELISA

    6 months

  • Serum Lactate dehydrogenase (LDH) levels

    LDHmeasured in IU/L using ELISA

    6 months

  • alanine aminotransferase (ALT)

    ALT measured in U/L using ELISA

    6 months

  • Aspartate aminotransferase (AST)

    AST measured in U/L using ELISA

    6 months

  • motor unit potential (MUP) duration

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds.

    6 months

  • motor unit peak-to-peak amplitude

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt

    6 months

  • motor unit area to amplitude ratio (AAR)

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR .

    6 months

  • muscle echo intenisity (EI)

    EI is assessed during muscle ultrasound evaluation means of computer-assisted grayscale histogram analysis of Adobe Photoshop . echo intensity was calculated based on a histogram analysis which expresses every pixel as a value between 0 (black) and 255 (white)..he following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)

    6 MONTHS

  • Childhood myositis assessment scale

    used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best)

    6 months

  • MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL (MDAAT)

    The MDAAT is a combined tool that includes the Myositis Disease Activity Assessment visual analog scale (VAS) (MYOACT) and the Myositis Intention to Treat Activities Index (MITAX).it Assesses 6 extramuscular organs to produce a global extramuscular score, and the muscle score, which gives a total disease activity index score. Scores range from 0-60 for the extramuscular MYOACT score and 0-70 for the total MYOACT score, and they range from 0-54 for the Extramuscular MITAX score and 0-63 for the total MITAX score. higher scores indicates worse outcome

    6 months

  • CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ)

    There are 30 items in the Disability Index; one item each in the Discomfort Index and Health Status Index. Score range. The range is 0-3. Higher scores reflect greater disability.

    6 months

  • HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)

    20 questions grouped into eight subscales (dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities). (score = 0 to 3 with higher score means worse outcome ). The highest score for any question determines the score for the subscale in question. The HAQ disability index is calculated as the sum of the scores for various subscales,divided by the number of subscales responded to, and results in a score between 0 and 3. higher score means worse outcome

    6months

  • MYOSITIS DAMAGE INDEX (MDI)

    The MDI measures specific manifestations in 11 organ systems The MDI also includes a series of visual analog scales (VAS) to quantify damage severity in a given organ system. The VAS are summed together for a potential score of 0-110 with higher scores has worse prognosis

    6months

  • PHYSICIAN GLOBAL ACTIVITY assessment

    visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome

    6 months

  • PATIENT/PARENT GLOBAL ACTIVITY assessment

    visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome

    6 months

Study Arms (4)

Group (I):juvenile dermatomyositis (JDM)

Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months. .

Diagnostic Test: strain elastography

Group (II):idiopathic inflammatory myopathies(IIM)

Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months. * •

Diagnostic Test: strain elastography

Group (III): juvenile control group

20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness . .

Diagnostic Test: strain elastography

Group (VI):adult control group

20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .

Diagnostic Test: strain elastography

Interventions

strain elastographyDIAGNOSTIC_TEST

strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.

Group (I):juvenile dermatomyositis (JDM)Group (II):idiopathic inflammatory myopathies(IIM)Group (III): juvenile control groupGroup (VI):adult control group

Eligibility Criteria

Age2 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study will be carried out on four groups: Group (I): thirty children diagnosed to have idiopathic inflammatory myopathies(IIM) * Group (II): thirty adults diagnosed to have IIM * Group (III):30 healthy children matching age and sex as first control group to children with IIM . * Group (VI):30 healthy adults matching age and sex as second control group to adults with IIM.

You may qualify if:

  • to fulfill criteria of diagnosis of childhood and adult idiopathic inflammatory myopathies

You may not qualify if:

  • Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales.
  • The presence of a associated illness that may result in nerve or muscle affection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha University Hospital

Banhā, Qalyubia Governorate, 13518, Egypt

RECRUITING

MeSH Terms

Conditions

Myositis

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Waleed A Hassan, MD

    Benha university- Qaluibya- Egypt

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Waleed Hassan, MD

CONTACT

Marwa Mahgoup, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

March 29, 2019

First Posted

April 1, 2019

Study Start

April 15, 2019

Primary Completion

November 1, 2020

Study Completion

November 1, 2020

Last Updated

October 19, 2020

Record last verified: 2020-10

Locations